Zacks' 7 Best Stocks for June, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X
  • Latest News
  • Most Popular
View All | Scroll Down Scroll Up

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/24/2013

Company Name Symbol %Change
MENTOR GRAPH MENT
2.59%
GENTIUM SPA GENT
2.47%
INFORMATION III
2.09%
AMER NATL BK AMNB
1.99%
ALLIANCE FIB AFOP
1.75%

Zacks Rank #1 Strong Buys

Analyst Blog

Print
Share

Data on ViroPharma's Cinryze

by Zacks Equity Research

January 18, 2013 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

ViroPharma (VPHM - Snapshot Report) recently announced that The Journal of Pediatrics published data in an article on Jan 14, 2013, which demonstrated that key product Cinryze (C1 esterase inhibitor [human]) is useful in providing relief from the symptoms of hereditary angioedema (HAE) attacks in pediatric patients. Cinryze also helped reduce the rate of attacks.
We note that Cinryze is approved in the US for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. In Europe, it is approved for routine prevention, pre-procedure prevention and acute treatment of angioedema attacks in adolescent and adult patients with HAE.
As of now, Cinryze is not approved for use in children. Cinryze is also not approved to treat HAE attacks or for procedural prophylaxis.
A study was conducted on four patients in the age group of 9-17 years who completed the pivotal prophylaxis trial. It was observed that HAE attacks reduced by almost two folds in these children when they were given Cinryze for prophylaxis as compared to the time period when they were given placebo.
We remind investors that in Nov 2012, ViroPharma had presented promising data on Cinryze from a post marketing study that evaluated the safety, tolerability and efficacy of Cinryze in escalating doses in patients with HAE who did not show sufficient treatment benefit with 1000 units every 3 or 4 days.
The data was presented at the American College of Allergy, Asthma and Immunology’s (ACAAI) annual congress.
Meanwhile, ViroPharma expects sales from Cinryze to come around $321 million in 2012, towards the lower end of its previously announced guidance of $320 million – $335 million. Approximately $311 to $312 million of total Cinryze sales was attributed to actual patient demand while an increase in channel inventories accounted for the remainder. Cinryze sales are expected in the range of $390 million - $400 million in North America in 2013.
Although the prospects for Cinryze look bright for ViroPharma, we remain concerned about the company’s dependence primarily on Cinryze for growth.
We have a Neutral recommendation on ViroPharma, which carries a Zacks Rank #3 (Hold). A pharma stock which currently looks attractive is Valeant Pharmaceuticals (VRX - Snapshot Report) which carries a Zacks Rank #1 (Strong Buy).

Read the full reports :

Email Print Share Rate Pos Rate Neg

Disclosure / Disclaimer Link
Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.
Quick Links

Services

My Account

Resources

Client Support

Follow Us

Facebook

Twitter

Linkedin

RSS

You Tube

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.

Copyright 2013 Zacks Investment Research

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.

Visit performance for information about the performance numbers displayed above.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.